{"success":true,"data":{"pressRelease":{"id":"167575","rtpr_id":"nPn9D9ZPDa-20261013","ticker":"NRSN","exchange":"NASDAQ","all_tickers":["NRSN","NRSNW"],"title":"NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones","author":"PR Newswire","published_at":"2026-10-13T12:30:01.356Z","article_body":"NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones\nPR Newswire\n\nCAMBRIDGE, Mass., Oct. 13, 2026\n\nShares continue to trade on Nasdaq pending the Panel's decision; minimum bid\nprice compliance already regained\n\nNear-term catalysts include a New Drug Submission to Health Canada targeted\nfor December 2026 and a decision on non-dilutive funding for the Phase 3\nPARAGON trial expected in Q1 2027\n\nCAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.\n(https://www.neurosense-tx.com/)  (NASDAQ: NRSN) (\"NeuroSense\" or the\n\"Company\"), a late-stage clinical biotechnology company focused on developing\ndisease-modifying treatments for neurodegenerative diseases, today announced\nthat its hearing before the Nasdaq Hearings Panel (the \"Panel\") is scheduled\nfor November 10, 2026, following its timely appeal of the October 1, 2026\nStaff Delisting Determination.\n\nThe appeal stays the suspension and delisting action, and NeuroSense's\nordinary shares and warrants are expected to continue trading on The Nasdaq\nCapital Market under \"NRSN\" and \"NRSNW,\" respectively, pending the Panel's\ndecision.\n\nManagement Commentary\n\n\"With bid-price compliance regained, we look forward to presenting the Panel\nwith our plan to achieve full compliance, while advancing PrimeC toward\nseveral important near-term milestones,\" said Alon Ben-Noon, Chief Executive\nOfficer of NeuroSense.\n\n\"PrimeC's Phase 2b results, published in JAMA Neurology, and FDA clearance to\ninitiate PARAGON provide a strong foundation for the next stage of\ndevelopment. Over the coming months, we expect to file our New Drug Submission\nwith Health Canada and receive a decision on non-dilutive grant funding that,\nif awarded, could support Phase 3 development while reducing our reliance on\nequity financing. We are also pursuing strategic business development\nopportunities.\"\n\nPlan to Regain Nasdaq Compliance\n\nNeuroSense has regained compliance with Nasdaq's $1.00 minimum bid price\nrequirement. The only remaining deficiency identified in the October 1 Staff\nDetermination is the $35 million minimum market value of listed securities\nrequirement under Rule 5550(b)(2).\n\nAt the hearing, the Company intends to present its plan to meet that\nrequirement or the alternative $2.5 million stockholders' equity standard\nunder Rule 5550(b)(1), including proposed measures to strengthen its balance\nsheet and stockholders' equity, together with implementation timelines.\n\nNeuroSense intends to request an exception period to execute its plan. The\nPanel may grant an exception of up to 180 days from the October 1 Staff\nDetermination, but there is no assurance that an exception will be granted or\nthat the Company will regain and maintain compliance.\n\nUpcoming PrimeC Milestones\n\n * Health Canada New Drug Submission for PrimeC in ALS: targeted for December\n2026.\n * Decision on non-dilutive grant funding for Phase 3 PARAGON: expected in Q1\n2027, subject to completion of the ongoing grant review.\nAbout NeuroSense\n\nNeuroSense Therapeutics is a late-clinical stage biotechnology company\ndeveloping novel treatments for severe neurodegenerative diseases, including\namyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's\nlead product candidate, PrimeC, is a novel oral therapy designed to target\nmultiple key biological pathways underlying disease progression, including\nneuroinflammation, oxidative stress and dysregulated iron metabolism.\n\nNeuroSense has recently completed analysis of long-term follow-up data from\nits Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology\nshowing slower functional decline in participants who received PrimeC from\nstudy start than in those who initially received placebo. The Company also\nreported changes across multiple biomarkers associated with ALS, including\nmicroRNAs, consistent with PrimeC's multi-target mechanism of action.\n\nNeuroSense has received clearance from the U.S. Food and Drug Administration\n(FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be\nconducted primarily in the United States. The Company is working with FDA on\nan optimized design for the study.\n\nFor additional information, we invite you to visit our website\n(http://www.neurosense-tx.com/)  and follow us on LinkedIn\n(https://www.linkedin.com/company/neurosense-therapeutics/mycompany/)\n, YouTube  (https://www.youtube.com/@neurosensetherapeutics5471) and X\n(https://twitter.com/NeurosenseT) . Information that may be important to\ninvestors may be routinely posted on our website and these social media\nchannels.\n\nAbout PrimeC\n\nPrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral\nformulation composed of a unique fixed-dose combination of two FDA-approved\ndrugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key\nmechanisms that contribute to neuron degeneration, inflammation, iron\naccumulation and impaired ribonucleic acid (\"RNA\") regulation, with the\npotential to inhibit disease progression.\n\nAbout ALS\n\nAmyotrophic lateral sclerosis (\"ALS\") is an incurable neurodegenerative\ndisease that causes progressive paralysis and, typically, death within 3 years\nof symptoms onset. Every year, more than 5,000 people are diagnosed with ALS\nin the U.S. alone, with an annual disease burden of $1 billion. The number of\npeople living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements\" that are subject to\nsubstantial risks and uncertainties. All statements, other than statements of\nhistorical fact, contained in this press release are forward-looking\nstatements. Forward-looking statements contained in this press release may be\nidentified by the use of words such as \"anticipate,\" \"believe,\" \"contemplate,\"\n\"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\" \"might,\" \"plan,\"\n\"potential,\" \"predict,\" \"project,\" \"target,\" \"aim,\" \"should,\" \"will,\" \"would,\"\nor the negative of these words or other similar expressions, although not all\nforward-looking statements contain these words. Forward-looking statements are\nbased on NeuroSense Therapeutics' current expectations and are subject to\ninherent uncertainties, risks and assumptions that are difficult to predict\nand include statements regarding the Nasdaq hearing process, the continued\nlisting and trading of the Company's securities pending the Panel's decision,\nthe Company's request for an exception period, the Company's plan to regain\ncompliance with Nasdaq's continued listing requirements, including through\ncompliance with the minimum market value of listed securities requirement or\nthe alternative stockholders' equity standard, the Company's proposed measures\nto strengthen its balance sheet and stockholders' equity and the timing and\neffectiveness of such measures, the anticipated milestones described in this\npress release and their timing, including the anticipated timing of the\nCompany's New Drug Submission to Health Canada and a decision regarding\npotential non-dilutive grant funding for the Phase 3 PARAGON trial, the\npotential receipt, timing and amount of such funding and its potential ability\nto support Phase 3 development and reduce the Company's reliance on equity\nfinancing, the Company's pursuit of strategic business development\nopportunities and the potential benefits thereof, and the potential of PrimeC.\nFurther, certain forward-looking statements, including statements regarding\nthe potential regulatory pathways for PrimeC, are based on assumptions as to\nfuture events that may not prove to be accurate. The future events and trends\nmay not occur and actual results could differ materially and adversely from\nthose anticipated or implied in the forward-looking statements. These risks\ninclude the potential for delay in the timing of the Phase 3 clinical trial\n(PARAGON) in ALS; potential delay in the Canadian New Drug Submission; the\nrisk that the Company will not be able to obtain financing on acceptable\nterms, or at all; the risk that the Company will not regain and maintain\ncompliance with the Nasdaq listing requirements; the risk that the Panel will\nnot grant the Company's request for an exception period; the risk that\nnon-dilutive grant funding for the PARAGON trial will not be awarded or will\nbe delayed; the risk that the strategic opportunities described will not\nmaterialize or result in the anticipated benefits to the Company; uncertainty\nregarding outcomes and the timing of current and future clinical trials; the\nrisk that PrimeC will not advance towards later-stage development; timing for\nreporting data, including from the study of PrimeC in Alzheimer's disease;\nthat the study will not be successful; and other risks and uncertainties set\nforth in NeuroSense's filings with the Securities and Exchange Commission\n(SEC). You should not rely on these statements as representing our views in\nthe future. More information about the risks and uncertainties affecting\nNeuroSense is contained under the heading \"Risk Factors\" in the Annual Report\non Form 20-F filed with the Securities and Exchange Commission on March 31,\n2026 and NeuroSense's subsequent filings with the SEC. Forward-looking\nstatements contained in this announcement are made as of this date, and\nNeuroSense undertakes no duty to update such information except as required\nunder applicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/neurosense-secures-nasdaq-hearing-date-as-primec-approaches-key-regulatory-and-funding-milestones-302906853.html\n(https://www.prnewswire.com/news-releases/neurosense-secures-nasdaq-hearing-date-as-primec-approaches-key-regulatory-and-funding-milestones-302906853.html)\n\nSOURCE NeuroSense\n\n\n\nFor further information: info@neurosense-tx.com, Tel: +972 (0)9 799 6183; Investor Relations: Or Eisenberg, or@neurosense-tx.com, Tel: +1315517554134\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1314973/NeuroSense-Therapeutics-Logo.jpg?id=OA3012470\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9D9ZPDa-20261013","title":"NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones","author":"PR Newswire","ticker":"NRSN","created":"2026-10-13T12:30:01.356Z","tickers":["NRSN","NRSNW"],"exchange":"NASDAQ","article_body":"NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones\nPR Newswire\n\nCAMBRIDGE, Mass., Oct. 13, 2026\n\nShares continue to trade on Nasdaq pending the Panel's decision; minimum bid\nprice compliance already regained\n\nNear-term catalysts include a New Drug Submission to Health Canada targeted\nfor December 2026 and a decision on non-dilutive funding for the Phase 3\nPARAGON trial expected in Q1 2027\n\nCAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.\n(https://www.neurosense-tx.com/)  (NASDAQ: NRSN) (\"NeuroSense\" or the\n\"Company\"), a late-stage clinical biotechnology company focused on developing\ndisease-modifying treatments for neurodegenerative diseases, today announced\nthat its hearing before the Nasdaq Hearings Panel (the \"Panel\") is scheduled\nfor November 10, 2026, following its timely appeal of the October 1, 2026\nStaff Delisting Determination.\n\nThe appeal stays the suspension and delisting action, and NeuroSense's\nordinary shares and warrants are expected to continue trading on The Nasdaq\nCapital Market under \"NRSN\" and \"NRSNW,\" respectively, pending the Panel's\ndecision.\n\nManagement Commentary\n\n\"With bid-price compliance regained, we look forward to presenting the Panel\nwith our plan to achieve full compliance, while advancing PrimeC toward\nseveral important near-term milestones,\" said Alon Ben-Noon, Chief Executive\nOfficer of NeuroSense.\n\n\"PrimeC's Phase 2b results, published in JAMA Neurology, and FDA clearance to\ninitiate PARAGON provide a strong foundation for the next stage of\ndevelopment. Over the coming months, we expect to file our New Drug Submission\nwith Health Canada and receive a decision on non-dilutive grant funding that,\nif awarded, could support Phase 3 development while reducing our reliance on\nequity financing. We are also pursuing strategic business development\nopportunities.\"\n\nPlan to Regain Nasdaq Compliance\n\nNeuroSense has regained compliance with Nasdaq's $1.00 minimum bid price\nrequirement. The only remaining deficiency identified in the October 1 Staff\nDetermination is the $35 million minimum market value of listed securities\nrequirement under Rule 5550(b)(2).\n\nAt the hearing, the Company intends to present its plan to meet that\nrequirement or the alternative $2.5 million stockholders' equity standard\nunder Rule 5550(b)(1), including proposed measures to strengthen its balance\nsheet and stockholders' equity, together with implementation timelines.\n\nNeuroSense intends to request an exception period to execute its plan. The\nPanel may grant an exception of up to 180 days from the October 1 Staff\nDetermination, but there is no assurance that an exception will be granted or\nthat the Company will regain and maintain compliance.\n\nUpcoming PrimeC Milestones\n\n * Health Canada New Drug Submission for PrimeC in ALS: targeted for December\n2026.\n * Decision on non-dilutive grant funding for Phase 3 PARAGON: expected in Q1\n2027, subject to completion of the ongoing grant review.\nAbout NeuroSense\n\nNeuroSense Therapeutics is a late-clinical stage biotechnology company\ndeveloping novel treatments for severe neurodegenerative diseases, including\namyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's\nlead product candidate, PrimeC, is a novel oral therapy designed to target\nmultiple key biological pathways underlying disease progression, including\nneuroinflammation, oxidative stress and dysregulated iron metabolism.\n\nNeuroSense has recently completed analysis of long-term follow-up data from\nits Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology\nshowing slower functional decline in participants who received PrimeC from\nstudy start than in those who initially received placebo. The Company also\nreported changes across multiple biomarkers associated with ALS, including\nmicroRNAs, consistent with PrimeC's multi-target mechanism of action.\n\nNeuroSense has received clearance from the U.S. Food and Drug Administration\n(FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be\nconducted primarily in the United States. The Company is working with FDA on\nan optimized design for the study.\n\nFor additional information, we invite you to visit our website\n(http://www.neurosense-tx.com/)  and follow us on LinkedIn\n(https://www.linkedin.com/company/neurosense-therapeutics/mycompany/)\n, YouTube  (https://www.youtube.com/@neurosensetherapeutics5471) and X\n(https://twitter.com/NeurosenseT) . Information that may be important to\ninvestors may be routinely posted on our website and these social media\nchannels.\n\nAbout PrimeC\n\nPrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral\nformulation composed of a unique fixed-dose combination of two FDA-approved\ndrugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key\nmechanisms that contribute to neuron degeneration, inflammation, iron\naccumulation and impaired ribonucleic acid (\"RNA\") regulation, with the\npotential to inhibit disease progression.\n\nAbout ALS\n\nAmyotrophic lateral sclerosis (\"ALS\") is an incurable neurodegenerative\ndisease that causes progressive paralysis and, typically, death within 3 years\nof symptoms onset. Every year, more than 5,000 people are diagnosed with ALS\nin the U.S. alone, with an annual disease burden of $1 billion. The number of\npeople living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements\" that are subject to\nsubstantial risks and uncertainties. All statements, other than statements of\nhistorical fact, contained in this press release are forward-looking\nstatements. Forward-looking statements contained in this press release may be\nidentified by the use of words such as \"anticipate,\" \"believe,\" \"contemplate,\"\n\"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\" \"might,\" \"plan,\"\n\"potential,\" \"predict,\" \"project,\" \"target,\" \"aim,\" \"should,\" \"will,\" \"would,\"\nor the negative of these words or other similar expressions, although not all\nforward-looking statements contain these words. Forward-looking statements are\nbased on NeuroSense Therapeutics' current expectations and are subject to\ninherent uncertainties, risks and assumptions that are difficult to predict\nand include statements regarding the Nasdaq hearing process, the continued\nlisting and trading of the Company's securities pending the Panel's decision,\nthe Company's request for an exception period, the Company's plan to regain\ncompliance with Nasdaq's continued listing requirements, including through\ncompliance with the minimum market value of listed securities requirement or\nthe alternative stockholders' equity standard, the Company's proposed measures\nto strengthen its balance sheet and stockholders' equity and the timing and\neffectiveness of such measures, the anticipated milestones described in this\npress release and their timing, including the anticipated timing of the\nCompany's New Drug Submission to Health Canada and a decision regarding\npotential non-dilutive grant funding for the Phase 3 PARAGON trial, the\npotential receipt, timing and amount of such funding and its potential ability\nto support Phase 3 development and reduce the Company's reliance on equity\nfinancing, the Company's pursuit of strategic business development\nopportunities and the potential benefits thereof, and the potential of PrimeC.\nFurther, certain forward-looking statements, including statements regarding\nthe potential regulatory pathways for PrimeC, are based on assumptions as to\nfuture events that may not prove to be accurate. The future events and trends\nmay not occur and actual results could differ materially and adversely from\nthose anticipated or implied in the forward-looking statements. These risks\ninclude the potential for delay in the timing of the Phase 3 clinical trial\n(PARAGON) in ALS; potential delay in the Canadian New Drug Submission; the\nrisk that the Company will not be able to obtain financing on acceptable\nterms, or at all; the risk that the Company will not regain and maintain\ncompliance with the Nasdaq listing requirements; the risk that the Panel will\nnot grant the Company's request for an exception period; the risk that\nnon-dilutive grant funding for the PARAGON trial will not be awarded or will\nbe delayed; the risk that the strategic opportunities described will not\nmaterialize or result in the anticipated benefits to the Company; uncertainty\nregarding outcomes and the timing of current and future clinical trials; the\nrisk that PrimeC will not advance towards later-stage development; timing for\nreporting data, including from the study of PrimeC in Alzheimer's disease;\nthat the study will not be successful; and other risks and uncertainties set\nforth in NeuroSense's filings with the Securities and Exchange Commission\n(SEC). You should not rely on these statements as representing our views in\nthe future. More information about the risks and uncertainties affecting\nNeuroSense is contained under the heading \"Risk Factors\" in the Annual Report\non Form 20-F filed with the Securities and Exchange Commission on March 31,\n2026 and NeuroSense's subsequent filings with the SEC. Forward-looking\nstatements contained in this announcement are made as of this date, and\nNeuroSense undertakes no duty to update such information except as required\nunder applicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/neurosense-secures-nasdaq-hearing-date-as-primec-approaches-key-regulatory-and-funding-milestones-302906853.html\n(https://www.prnewswire.com/news-releases/neurosense-secures-nasdaq-hearing-date-as-primec-approaches-key-regulatory-and-funding-milestones-302906853.html)\n\nSOURCE NeuroSense\n\n\n\nFor further information: info@neurosense-tx.com, Tel: +972 (0)9 799 6183; Investor Relations: Or Eisenberg, or@neurosense-tx.com, Tel: +1315517554134\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1314973/NeuroSense-Therapeutics-Logo.jpg?id=OA3012470\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T12:30:01.474743009Z","server_sent_at_ms":1791894601474},"received_at":"2026-10-13T12:30:01.527Z","source_url":"https://www.prnewswire.com/news-releases/neurosense-secures-nasdaq-hearing-date-as-primec-approaches-key-regulatory-and-funding-milestones-302906853.html"},"analysis":{"id":"155872","press_release_id":"167575","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Nasdaq delisting proceedings: Panel decision on continued listing is uncertain","Remaining deficiency is the $35M minimum market value of listed securities requirement","No assurance an up-to-180-day exception will be granted","Phase 3 funding dependent on non-dilutive grant decision not yet awarded","Explicit risk of inability to obtain financing on acceptable terms"],"eventType":"regulatory","narrative":"NeuroSense's Nasdaq Hearings Panel appeal is scheduled for November 10, 2026, following the October 1 Staff Delisting Determination; shares and warrants continue trading under NRSN and NRSNW pending the Panel's decision.\n\nThe company has already regained compliance with the $1.00 minimum bid price requirement, leaving the $35 million minimum market value of listed securities standard as the sole remaining deficiency. NeuroSense will present a plan to meet that standard or the alternative $2.5 million stockholders' equity requirement, and will request an exception period of up to 180 days.\n\nNear-term catalysts include a Health Canada New Drug Submission for PrimeC in ALS targeted for December 2026 and a decision on non-dilutive grant funding for the Phase 3 PARAGON trial expected in Q1 2027, which could reduce reliance on equity financing.\n\nThere is no assurance the Panel will grant an exception or that NeuroSense will regain and maintain compliance.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"NRSN buys time before the Nasdaq Panel -- delisting risk stays live while PrimeC regulatory and funding catalysts hit December 2026 and Q1 2027."},"keyFigures":{"customDimensions":{"hearing_date":"November 10, 2026","grant_funding_decision":"Q1 2027","minimum_mvx_requirement":"$35 million","health_canada_nda_target":"December 2026","staff_determination_date":"October 1, 2026","max_exception_period_days":180,"alternative_stockholders_equity_standard":"$2.5 million"}},"quotedText":"With bid-price compliance regained, we look forward to presenting the Panel with our plan to achieve full compliance, while advancing PrimeC toward several important near-term milestones","namedEntities":{"people":[{"name":"Alon Ben-Noon","role":"CEO"},{"name":"Or Eisenberg","role":"Investor Relations"}],"products":["PrimeC","PARAGON","PARADIGM"],"companies":[{"name":"NeuroSense Therapeutics Ltd.","ticker":"NRSN","relationship":"filer"},{"name":"Nasdaq Hearings Panel","relationship":"regulator"},{"name":"Health Canada","relationship":"regulator"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$35 million","context":"Nasdaq minimum market value of listed securities requirement (Rule 5550(b)(2))"},{"amount":"$2.5 million","context":"alternative stockholders' equity standard (Rule 5550(b)(1))"},{"amount":"$1.00","context":"Nasdaq minimum bid price requirement (compliance regained)"},{"amount":"$1 billion","context":"annual ALS disease burden in the U.S."}]},"materialImpact":{"score":3,"reasoning":"Delisting risk is a material listing-compliance event: NeuroSense timely appealed an October 1 Staff Delisting Determination and will argue its compliance plan before the Nasdaq Panel on November 10, 2026, with trading continuing pending the decision. Mitigating facts -- $1.00 minimum bid compliance already regained and near-term PrimeC milestones -- reduce severity, but the Panel may deny the exception request."},"tickerRelevance":{"others":[],"primary":"NRSN"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"mitigants":["bid-price compliance regained","near-term pipeline catalysts"],"tickerTier":"micro-cap","eventGravity":"listing-compliance-appeal","issuerAuthored":true}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"mixed","material_impact_score":3,"narrative":"NeuroSense's Nasdaq Hearings Panel appeal is scheduled for November 10, 2026, following the October 1 Staff Delisting Determination; shares and warrants continue trading under NRSN and NRSNW pending the Panel's decision.\n\nThe company has already regained compliance with the $1.00 minimum bid price requirement, leaving the $35 million minimum market value of listed securities standard as the sole remaining deficiency. NeuroSense will present a plan to meet that standard or the alternative $2.5 million stockholders' equity requirement, and will request an exception period of up to 180 days.\n\nNear-term catalysts include a Health Canada New Drug Submission for PrimeC in ALS targeted for December 2026 and a decision on non-dilutive grant funding for the Phase 3 PARAGON trial expected in Q1 2027, which could reduce reliance on equity financing.\n\nThere is no assurance the Panel will grant an exception or that NeuroSense will regain and maintain compliance.","key_figures":{"customDimensions":{"hearing_date":"November 10, 2026","grant_funding_decision":"Q1 2027","minimum_mvx_requirement":"$35 million","health_canada_nda_target":"December 2026","staff_determination_date":"October 1, 2026","max_exception_period_days":180,"alternative_stockholders_equity_standard":"$2.5 million"}},"named_entities":{"people":[{"name":"Alon Ben-Noon","role":"CEO"},{"name":"Or Eisenberg","role":"Investor Relations"}],"products":["PrimeC","PARAGON","PARADIGM"],"companies":[{"name":"NeuroSense Therapeutics Ltd.","ticker":"NRSN","relationship":"filer"},{"name":"Nasdaq Hearings Panel","relationship":"regulator"},{"name":"Health Canada","relationship":"regulator"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$35 million","context":"Nasdaq minimum market value of listed securities requirement (Rule 5550(b)(2))"},{"amount":"$2.5 million","context":"alternative stockholders' equity standard (Rule 5550(b)(1))"},{"amount":"$1.00","context":"Nasdaq minimum bid price requirement (compliance regained)"},{"amount":"$1 billion","context":"annual ALS disease burden in the U.S."}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:30:18.354Z","global_importance":25,"audience_relevance":20,"importance_components":{"mitigants":["bid-price compliance regained","near-term pipeline catalysts"],"tickerTier":"micro-cap","eventGravity":"listing-compliance-appeal","issuerAuthored":true}},"durationMs":8372,"modelName":"glm-5.3-flashx"}}